Predictors of Long-Term Mortality in Patients With Acute Heart Failure

Jin, Mengchao; Wei, Siqi; Gao, Rongrong; Wang, Kai; Xu, Xuejuan; Yao, Wenming; Zhang, Haifeng; Zhou, Yanli; Xu, Duo; Zhou, Fang; Li, Xinli

doi:10.1536/ihj.16-219

Cited by 15 publications

(13 citation statements)

References 53 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In DCMP patients, myocardial NPPB expression was significantly higher (170 [38-369] versus 2 [1-25] relative units; P < 0.001), whereas CORIN expression was significantly lower (6 [2][3][4][5][6][7][8][9][10][11][12][13][14][15] versus 19 [14-31] relative units; P = 0.005) than in the Tx recipients (Figure 1). Strong inverse correlations were observed between CORIN and NPPB expression (r = NATRIURETIC PEPTIDE PROCESSING AND CORIN −0.585; P < 0.001), plasma ProBNP levels (r = −0.517; P < 0.001), and proBNP/BNP ratios (r = −0.362; P < 0.005).…”

Section: Corin and Nppb Expressionmentioning

confidence: 99%

“…The biological activity of the cleaved BNP is 8-fold greater than the unprocessed proBNP form. 3,4) Interestingly, as the concentration of BNP in the plasma increases, ventricular function declines, and thus, the BNP levels are useful for diagnosing left ventricular (LV) dysfunction and for stratifying and guiding therapy for patients with heart failure; 1,[5][6][7] however, patients with extreme heart failure and high circulating BNP levels (as-sessed with the standard clinical conventional assays) often display blunted BNP-mediated cardiovascular and renal effects. 8,9) Furthermore, the infusion of recombinant BNP in patients with acute heart failure promptly leads to symptomatic improvement.…”

mentioning

confidence: 99%

See 1 more Smart Citation

Natriuretic Peptide Processing in Patients with and Without Left Ventricular Dysfunction

et al. 2019

View full text Add to dashboard Cite

This study aimed to examine the relationship between corin expression and circulating brain natriuretic peptide in patients with left ventricular (LV) dysfunction. Circulating levels of B-type natriuretic peptide (BNP) can be an indicator of LV dysfunction. The 32amino-acid BNP is cleaved by corin, a cardiac serine protease, from its108-amino-acid pro-brain natriuretic peptide (proBNP) precursor. This study included 25 patients with idiopathic dilated cardiomyopathy (DCMP) and LV dysfunction and 44 heart transplant recipients with normal LV function who underwent diagnostic left and right heart catheterization. Blood samples were used to determine the ratio of plasma proBNP/BNP levels, and LV endomyocardial biopsies were used to determine the expression of NPPB, which encode BNP and corin, respectively, by quantitative reverse transcription-polymerase chain reaction. Patients with DCMP revealed worse hemodynamic profiles and higher plasma proBNP and BNP levels than those of the transplant recipients. Myocardial NPPB expression was higher and CORIN expression was lower in the DCMP patients than in the transplant recipients. CORIN expression significantly correlated with NPPB expression (r = −0.585; P < 0.001), ejection fraction (EF; r = 0.694; P < 0.01), LV end-diastolic pressure (r = −0.373; P < 0.05), and indexed end-diastolic LV volume (r = −0.452; P < 0.001). In addition, the plasma proBNP/BNP levels inversely correlated with the CORIN expression (r = −0.362; P < 0.005). Decreased myocardial CORIN expression and the corresponding higher levels of circulating unprocessed proBNP in DCMP may partly account for the relative BNP resistance observed in patients with LV dysfunction.

show abstract

Section: Corin and Nppb Expressionmentioning

confidence: 99%

mentioning

confidence: 99%

Natriuretic Peptide Processing in Patients with and Without Left Ventricular Dysfunction

et al. 2019

View full text Add to dashboard Cite

show abstract

“…Heart failure (HF) is the main factor leading to economic loss due to poor prognosis and a high mortality rate 1. In the USA, there are at least 5 000 000 patients with decreased contractile function; meanwhile, there is also the same number of patients with the same disease in Western Europe 2 3.…”

Section: Introductionmentioning

confidence: 99%

Effect of vitamin D on ventricular remodelling in heart failure: a meta-analysis of randomised controlled trials

et al. 2018

View full text Add to dashboard Cite

ObjectivesThe level of vitamin D is considered to be associated with the development and progression of heart failure (HF). However, it is still unclear whether supplementation of vitamin D could improve ventricular remodelling in patients with HF. This study aimed to systematically evaluate the influence and safety of additional vitamin D supplementation on ventricular remodelling in patients with HF.DesignThis study is a meta-analysis of randomised controlled trials (RCTs).SettingThe PubMed, EMBASE, CNKI, Cochrane library, Web of Science databases and grey literature were searched for RCTs regarding the effect of vitamin D on ventricular remodelling in patients with HF (from database creation to October 2017). RevMan V.5.3 software was employed for data analysis.ParticipantsSeven RCTs with a total of 465 patients, including 235 cases in the vitamin D group and 230 cases in the control group, were included.Primary and secondary outcome measuresLeft ventricular end-diastolic dimension (LVEDD), left ventricular ejection fraction (LVEF) and the incidence of adverse reactions.ResultsCompared with the control group, a decrease in the LVEDD (mean difference (MD)=−2.31 mm, 95% CI −4.15 to −0.47, p=0.01) and an increase in the LVEF (MD=4.18%, 95% CI 0.36 to 7.99, p=0.03) were observed in the vitamin D group. Subgroup analysis also revealed a reduced LVEDD in adults (>18 years) and adolescents (<18 years) of the vitamin D group relative to that in those of the control group. High-dose vitamin D (>4000 IU/day) was more effective at reducing the LVEDD than low-dose vitamin D (<4000 IU/day). Moreover, vitamin D supplementation was more effective at reducing the LVEDD and increasing the LVEF in patients with reduced ejection fraction than in patients without reduced ejection fraction.ConclusionVitamin D supplementation inhibits ventricular remodelling and improves cardiac function in patients with HF.Trial registration numberCRD42017073893.

show abstract

“…Of these, soluble suppression of tumorigenicity 2 (sST2), a member of the interleukin (IL)-1 receptor family, has emerged to be a promising marker of myocardial stress 7. Thus, it has been shown to be predictive of adverse clinical outcomes in different cardiovascular diseases, such as stable coronary artery disease,8 acute coronary syndrome,9 and acute10 as well as chronic heart failure 11…”

Section: Introductionmentioning

confidence: 99%